Press Release: Novartis and Amgen announce -2-

3. Genin et al 2011; Liu at al 2013; Jansen et al 2015

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Eric Althoff Gonzalo Linares

Novartis Global Media Relations Novartis Global Drug Development Communications

+41 61 324 7999 (direct) +41 61 324 5117 (direct)

+41 79 593 4202 (mobile) +41 79 386 7432 (mobile)

eric.althoff@novartis.com gonzalo.linares@novartis.com

Angela Fiorin

Novartis Global Pharma Communications

+ 41 61 324 8631 (direct)

+ 41 79 752 6955 (mobile)

angela.fiorin@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF): http://hugin.info/134323/R/2146869/823238.pdf

This announcement is distributed by Nasdaq Corporate Solutions on behalf

of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

November 02, 2017 16:30 ET (20:30 GMT)